NCT04872166View on ClinicalTrials.gov

A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

June 7, 2021

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2027

Conditions
Advanced Solid TumorMetastatic Breast Cancer
Interventions
DRUG

BTX-A51

One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of up to 5 days per weekf.

Trial Locations (6)

32746

RECRUITING

Florida Cancer Specialists, Lake Mary

34232

RECRUITING

Florida Cancer Specialists, Sarasota

37203

RECRUITING

SCRI Oncology Partners, Nashville

COMPLETED

Tennessee Oncology, PLLC, Nashville

45219

COMPLETED

The Linder Research Center at The Christ Hospital, Cincinnati

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Edgewood Oncology Inc.

INDUSTRY